By Helena Smolak


Ozempic maker Novo Nordisk signed a research collaboration with U.S. biotech company Metaphore Biotechnologies to develop up to two advanced obesity treatments, which could cost the company up to $600 million.

Metaphore Biotechnologies said on Thursday that the Danish drug company, which makes weight-loss drugs Ozempic and Wegovy, will use Metaphore's tech platform, which combines machine learning with molecular mimicry, to develop the treatments.

This is the third research and development deal with Metaphore Biotechnologies' parent company Flagship Pioneering.


Write to Helena Smolak at helena.smolak@wsj.com


(END) Dow Jones Newswires

05-09-24 1030ET